Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2
Open accessThe DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index; 51 of the 69 sources its claims cite were checked for support.
Abstract
While macrophage heterogeneity during metabolic dysfunction-associated steatohepatitis (MASH) has been described, the fate of these macrophages during MASH regression is poorly understood. Comparing macrophage heterogeneity during MASH progression vs regression, we identified specific macrophage subpopulations that are critical for MASH/fibrosis resolution. We elucidated the restorative pathways and gene signatures that define regression-associated macrophages and establish the importance of TREM2 + macrophages during MASH regression. Liver-resident Kupffer cells are lost during MASH and are replaced by four distinct monocyte-derived macrophage subpopulations. Trem2 is expressed in two macrophage subpopulations: i) monocyte-derived macrophages occupying the Kupffer cell niche (MoKC) and ii) lipid-associated macrophages (LAM). In regression livers, no new transcriptionally distinct macrophage subpopulation emerged. However, the relative macrophage composition changed during regression compared to MASH. While MoKC was the major macrophage subpopulation during MASH, they decreased during regression. LAM was the dominant macrophage subtype during MASH regression and maintained Trem2 expression. Both MoKC and LAM were enriched in disease-resolving pathways. Absence of TREM2 restricted the emergence of LAMs and formation of hepatic crown-like structures. TREM2 + macrophages are functionally important not only for restricting MASH-fibrosis progression but also for effective regression of inflammation and fibrosis. TREM2 + macrophages are superior collagen degraders. Lack of TREM2 + macrophages also prevented elimination of hepatic steatosis and inactivation of HSC during regression, indicating their significance in metabolic coordination with other cell types in the liver. TREM2 imparts this protective effect through multifactorial mechanisms, including improved phagocytosis, lipid handling, and collagen degradation.
Overview
CoChat Summary
## TL;DR
Using two mouse models of MASH, the paper shows that TREM2+ lipid-associated macrophages (LAMs) are the main restorative macrophage population during regression and are needed for fibrosis resolution. Loss of TREM2 impairs collagen resorption, steatosis clearance, and hepatic stellate cell inactivation.
## Key findings
- In Foz/Foz mice, switching from Western diet to chow for regression improved MASH within 4 weeks and continued through 8 weeks, but Foz::Trem2−/− mice had markedly impaired recovery: they failed to eliminate hepatic steatosis and had significantly worse fibrosis resolution.
- Fibrosis resolution was quantified as 70% at 8 weeks in Foz/Foz mice versus 30% at 8 weeks in Foz::Trem2−/− mice; the linear regression slopes were −0.087 vs −0.039, respectively.
- scRNAseq of 18 immune cell clusters identified 4 monocyte-derived macrophage populations emerging during MASH; during regression, LAMs (cluster 2) remained constant and became the major macrophage subpopulation, while MoKC shrank.
- TREM2+ macrophages were enriched for phagocytosis, anti-fibrosis, ECM degradation, and lipid/lipoprotein handling, whereas TREM2-low macrophages were enriched for inflammation, cytokine signaling, and cell death.
- Absence of TREM2 reduced GPNMB+ LAMs and hCLS in both MASH and regression, increased inflammatory macrophages, and impaired collagen degradation; in BMDMs, Trem2−/− cells were less efficient at collagen degradation than WT.
- In the second MASH model (WD + 30% fructose in drinking water), Trem2−/− mice developed more severe MASH/fibrosis, and about 60% progressed spontaneously to HCC with an average of 5 tumors/liver of average diameter 2.5 mm.
## Methods
- Two preclinical mouse models were used: Foz/Foz mice and Trem2−/− mice on a C57BL/6J background, plus Foz::Trem2−/− crosses; mice were fed Western diet or WD + 30% fructose to induce MASH, then some were switched to chow for regression.
- Regression in the Foz model was assessed at 4 and 8 weeks after WD→chow switch; a separate cohort stayed on WD for 20 weeks as a disease-control group.
- The main analyses included scRNAseq of immune cells from healthy, MASH, and regression livers; flow cytometry, immunohistochemistry, Luminex cytokine/chemokine profiling, gene expression analysis, and collagenase/collagen degradation assays. Group comparisons used ANOVA and Student’s t test.
## Limitations
- The paper states that the role of hepatic LAM/hCLS in MASH “remains unresolved” and that the mechanisms by which TREM2 modulates HSC inactivation and hepatic lipid metabolism during regression “need further investigation.”
- The paper notes that the myeloid population may need “longer time to return to homeostasis,” implying that the 8-week regression window may be too short to capture full recovery.
- The text makes evident that much of the mechanistic work is based on mouse models rather than direct human intervention studies (text-evident).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
39 Valid · 2 Not valid · 6 Not checked · 132 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“and fibrotic scars (SAM) (6)”
§ Lipid-associated macrophages’ promotion of fibrosis resolution during MASH regression requires TREM2 > Abstract
What the sources say
- Supportedcites [6] P. Ramachandran, Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512– 518 (2019), 10.1038/s41586-019-1631-3. 31597160 PMC6876711 source
The Results section, “Distinct macrophage subpopulations inhabit the fibrotic niche” (page not supplied), reports that scar-associated macrophages (SAMΦ) were localized in collagen-positive scar regions and accumulated within the fibrotic niche. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“MASH is associated with the emergence of lipid-associated macrophages (LAM) that highly express Trem2 along with Cd9, Gpnmb, and Spp1 (3–5)”
§ Lipid-associated macrophages’ promotion of fibrosis resolution during MASH regression requires TREM2 > Abstract
What the sources say
- Partly supportedcites [3] A. Remmerie, Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver. Immunity 53, 641– 657.e614 (2020). 32888418 PMC7501731 sourceExperimental — accuracy not yet measured
The Results section, “Hepatic Lipid-Associated Macs Differentiate in MAFLD” (page unavailable), identifies hepatic LAMs in diet-induced fatty liver disease and reports increased Cd9 and Trem2 expression and Spp1 enrichment. The Discussion says LAMs appeared in later disease stages, consistent with an association with steatohepatitis. The paper does not establish high Gpnmb expression in these cells; its GPNMB flow-cytometry test gave no signal above controls. (LLM, conf=0.86)
- Partly supportedcites [4] D. A. Jaitin, Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell 178, 686– 698.e614 (2019). 31257031 PMC7068689 sourceExperimental — accuracy not yet measured
The Results section, “Lipid-associated macrophages are characterized by Trem2 expression in mice and humans” (page not provided), identifies LAMs in obese adipose tissue as expressing Trem2 and Cd9 and reports LAM-like macrophages in mouse liver under high-fat-diet conditions. The paper does not establish their emergence specifically in MASH or identify Gpnmb as part of the reported LAM signature; it mentions Spp1 as differing among macrophage subsets, not as a confirmed high-expression LAM marker. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [5] J. S. Seidman, Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis. Immunity 52, 1057– 1074.e1057 (2020). 32362324 PMC7305990 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“are equivalent to the scar-associated macrophages (SAM) in human MASH (6–8)”
§ Lipid-associated macrophages’ promotion of fibrosis resolution during MASH regression requires TREM2 > Abstract
What the sources say
- Partly supportedcites [6] P. Ramachandran, Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512– 518 (2019), 10.1038/s41586-019-1631-3. 31597160 PMC6876711 sourceExperimental — accuracy not yet measured
The Results section ('Pro-fibrogenic phenotype of scar-associated macrophages'; page unavailable) reports expansion of scar-associated macrophages (SAMΦ) in patients with NASH, now termed MASH. Our copy does not identify these cells as LAMs or establish that the two populations are equivalent. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [7] T. Fabre, Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation. Sci. Immunol. 8, eadd8945 (2023). 37027478 source
- Partly supportedcites [8] C. Zwicker, A. Bujko, C. L. Scott, Hepatic macrophage responses in inflammation, a function of plasticity, heterogeneity or both? Front. Immunol. 12, 690813 (2021). 34177948 PMC8220199 sourceExperimental — accuracy not yet measured
The Murine Hepatic Macrophages section says alignment of murine LAMs and human SAMs showed significant overlap, suggesting they could be equivalent populations. It does not establish equivalence as fact, and it describes human SAMs in fibrotic or cirrhotic livers rather than specifically in human MASH. Page numbers are unavailable in the supplied copy. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“LAMs/SAMs increase with MASH severity (3, 10)”
§ Lipid-associated macrophages’ promotion of fibrosis resolution during MASH regression requires TREM2 > Abstract
What the sources say
- Partly supportedcites [3] A. Remmerie, Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver. Immunity 53, 641– 657.e614 (2020). 32888418 PMC7501731 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says hepatic LAMs were identified only in later disease stages, correlating with worsening disease and fibrosis; the mouse model developed NASH at later time points. The Results section on hepatic LAMs (page not provided) notes overlap with scar-associated macrophages (SAMs) in fibrotic human livers, but does not show that SAMs increase with MASH severity. (LLM, conf=0.85)
- Partly supportedcites [10] S. Daemen, Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep. 34, 108626 (2021). 33440159 PMC7877246 sourceExperimental — accuracy not yet measured
In Results (‘MdMs and Aggregate Formation in the NASH’; page unavailable), LAM/C-LAM markers are absent or rare with a standard diet but abundant in steatotic livers of high-fat-diet-fed mice. The paper says some macrophages share genes associated with SAMs from human cirrhosis; it does not show that SAM numbers increase with MASH severity or establish a severity-dependent increase for both populations. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“analyses of two publicly available scRNAseq datasets (3, 9) indicate that macrophages are the major cell types that express TREM2 in the MASH livers”
§ Lipid-associated macrophages’ promotion of fibrosis resolution during MASH regression requires TREM2 > Results > TREM2 in MASH.
What the sources say
- Partly supportedcites [3] A. Remmerie, Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver. Immunity 53, 641– 657.e614 (2020). 32888418 PMC7501731 sourceExperimental — accuracy not yet measured
The Results section, “Hepatic Lipid-Associated Macs Differentiate in MAFLD” (page unavailable), reports increased Trem2 expression across macrophage subsets in fatty-liver mice. It does not establish that macrophages are the major TREM2-expressing cell type across all cells in MASH livers: the study’s single-cell analysis was restricted to CD45+ immune cells. (LLM, conf=0.83)
- Partly supportedcites [9] M. Guilliams, Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell 185, 379– 396.e338 (2022). 35021063 PMC8809252 sourceExperimental — accuracy not yet measured
The Supplemental figures (p. 50) quantify Gpnmb and Trem2 transcripts relative to the macrophage marker Adgre1, linking Trem2 to hepatic macrophages. But the passage concerns tissue regions, not a comparison of TREM2 expression across cell types in MASH livers; it does not establish that macrophages are the major TREM2-expressing cell type there. (LLM, conf=0.78)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
111 more claims · 12 with their cited sources checked
Create a free account to see all 179 claims and every source verdict.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the majority of murine studies to date have suggested a role for LAMs/LAM-like KCs in tissue repair, contributing to dead cell and lipid clearance, thus reducing lipotoxic stress, and preventing uncontrolled inflammation (36, 108, 122–126)”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in experimental liver fibrosis in murine models, TREM2-deficient macrophages failed to acquire reparative phenotypes, showed impaired efferocytosis, and exacerbated fibrogenesis (36, 122–126).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with these findings, Ganguli et al. (10) identified Mo-KCs and LAMs as the predominant macrophage populations in MASH.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While Mo-KCs predominate during active disease, LAMs become dominant during regression, maintaining TREM2 expression.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Notably, during disease regression, fibrosis resolution was associated not with the emergence of new macrophage subsets but with a shift in population dynamics.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [10]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“From the 18 different immune cell clusters (SI Appendix, Fig. S3 A and B and Dataset S1), we focused our analysis on 6 monocyte/macrophage clusters (clusters 0, 1, 2, 5, and 15) (Fig. 3A).”
§ Lipid-associated macrophages’ promotion of fibrosis resolution during MASH regression requires TREM2 > Results > Macrophage Heterogeneity during MASH Progression and Regression.
Reported 6 · recomputed 23
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lipid-associated macrophages’ promotion of fibrosis resolution during MASH regression requires TREM2 > Results > Macrophage Heterogeneity during MASH Progression and Regression.
“From the 18 different immune cell clusters (SI Appendix, Fig. S3 A and B and Dataset S1), we focused our analysis on 6 monocyte/macrophage clusters (clusters 0, 1, 2, 5, and 15) (Fig. 3A).”
§ Lipid-associated macrophages’ promotion of fibrosis resolution during MASH regression requires TREM2 > Results > Macrophage Heterogeneity during MASH Progression and Regression.
“In MASH livers the Timd4+EmKCs were depleted, as reported (3, 5, 10, 34), and were replaced by four distinct Timd4-clusters (clusters 5, 15, 1, 2) that were derived from circulating monocytes, also known as recruited macrophages (RM) (Fig. 3 A−C and SI Appendix, Fig. S3C).”
Citations
Cites
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 1×
“Most of the existing knowledge regarding liver fibrosis resolution is derived from mouse models of chemical (CCl 4 or acetaminophen) - induced fibrosis and regression ( 17 – 21 ).”
Self-citationResolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784 · cited 4×
“Although TREM2 has been shown to be up - regulated in advanced MASH livers ( 6 , 16 ), at what stage TREM2 is induced during the disease progression and what event (such as steatosis, fibrosis, or hepatocyte death) triggers TREM2 upregulation are not clear.”
InfluentialSelective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner
Jaitin, D. A., Adlung, L., Thaiss, C. A., Weiner, A., Li, B., Descamps, H., Lundgren, P., Bleriot, C., Liu, Z., Deczkowska, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.054 · Cited by 1,377 · cited 3×
“While some studies reported increased body and liver weight in Trem2 −/− mice on HFD or WD ( 4 , 12 , 40 ), the Winn et al. study ( 41 ) and ours did not observe such differences.”
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110 · cited 1×
“Inflammasome activation is a hallmark of MASH livers ( 42 ), and we found that TREM2 restrains NLRP3 inflammasome activation.”
Self-citationRamachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001 · cited 3×
“While the restorative macrophages that play key roles in fibrosis resolution have been studied in the context of chemical - induced fibrosis regression (17, 20), their identity during MASH resolution is unknown.”
Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
Guilliams, M., Bonnardel, J., Haest, B., Vanderborght, B., Wagner, C., Remmerie, A., Bujko, A., Martens, L., Thoné, T., Browaeys, R., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.018 · Cited by 985
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945 · cited 1×
“2 F ), indicating that Trem2 −/− MASH livers have enhanced NLRP3 inflammasome activation, a key activator of liver inflammation in MASH (25, 26).”
Self-citationThe role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941 · cited 1×
“Macrophages play a central role in orchestrating MASH progression and resolution ( 37 ).”
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805 · cited 1×
“Therefore, to evaluate the effective reduction in collagen levels following the dietary switch, the SR score of each regression group was normalized to the corresponding MASH SR score (at 12 wk WD just before the switch) as previously reported for CCl 4 fibrosis resolution studies ( 33 ).”
Self-citation
Research works printed but not linked: 1
- S. Ganguly, Lipid Associated Macrophages’ Promotion of Fibrosis Resolution during MASH regression requires TREM2. GEO. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261829. Deposited 18 March 2024. PMC11363294 39172787
Cited by
MASH: the nexus of metabolism, inflammation, and fibrosis
Steinberg, G. R., Carpentier, A. C., & Wang, D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186420 · Cited by 158
Spatially restricted and ontogenically distinct hepatic macrophages are required for tissue repair
De Ponti, F. F., Bujko, A., Liu, Z., Collins, P. J., Schuermans, S., Maueroder, C., Amstelveen, S., Thoné, T., Martens, L., McKendrick, J. G., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.01.002 · Cited by 94
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
“Moreover, the subpopulation of TREM2-expressing lipid-associated macrophages is important for the efferocytosis of dying hepatocytes and repair [267, 268].”
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
“A recent study indicated that macrophage heterogeneity in livers undergoing MASH regression closely mirrors that of active MASH [25].”
InfluentialSelf-citationTREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity
Cui, H., Banerjee, S., Xie, N., Hussain, M., Jaiswal, A., Liu, H., Kulkarni, T., Antony, V. B., Liu, R.-M., Colonna, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57024-0 · Cited by 74
Regulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction–Associated Steatohepatitis
Kisseleva, T., Ganguly, S., Murad, R., Wang, A., & Brenner, D. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.010 · Cited by 86
Self-citationThe spatial and temporal activation of macrophages during fibrosis
Behmoaras, J. V., Mulder, K., Ginhoux, F., & Petretto, E. G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01186-x · Cited by 86
The Landscape of SPP1 + Macrophages Across Tissues and Diseases: A Comprehensive Review
Palma, A. (2025) · Immunology · doi:10.1111/imm.13952 · Cited by 82
Liver macrophages: development, dynamics, and functions
Nusse, Y., & Kubes, P. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01298-3 · Cited by 50
Martin, O. P., Wallace, M. S., Oetheimer, C., Patel, H. B., Butler, E. C., Wong, L. P., Huang, P., Elbaz, J., Costentin, C., Salloum, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02255-y · Cited by 45
“…lipid-or scar-associated macrophages (LAMs or SAMs) ( TREM2 , SPP1 , CD9 , LGALS1/3 , FABP3/4 and ANXA1) , suggested as controlling fibrosis 24,25 , but also maintained expression of S100A9 (normally lost on macrophage differentiation 19 ) and the transcription factor CEBPB (together with…”
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
de Zawadzki, A., Leeming, D. J., Sanyal, A. J., Anstee, Q. M., Schattenberg, J. M., Friedman, S. L., Schuppan, D., & Karsdal, M. A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.039 · Cited by 51
Functional diversity of disorder-specific macrophages involved in various diseases
Mitsui, Y., & Satoh, T. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00390-5 · Cited by 42
“Hepatic LAMs are characterized by high expression of TREM2 , GPNMB , and CD9 , and are strongly associated with dysfunctional lipid metabolism and chronic liver inflammation [81, 99, 100].”
InfluentialMetabolic reprogramming of immune cells in MASH
Ma, C., Wang, S., Dong, B., & Tian, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001371 · Cited by 36
Rohm, T. V., Reis, F. C. G., Rocha, K. C. E., Isaac, R., Strayer, S., Murphy, C., Bandyopadhyay, G. K., Gao, H., Ganguly, S., Nguyen, T. T. B., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.033 · Cited by 33
Self-citationThe role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies
Ma, X., Qiu, J., Zou, S., Tan, L., & Miao, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1494250 · Cited by 35
The pathogenesis of hepatic steatosis in MASLD: a lipid droplet perspective
Krahmer, N., Walther, T. C., & Farese, R. V. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198334 · Cited by 35
“Trem2-deficient mice exhibit worsened liver inflammation and injury, while TREM2 overexpression enhances lipid handling and reduces liver damage in mice (23).”
TREM2-expressing macrophages in liver diseases
Wang, X., Qiu, Z., Zhong, Z., & Liang, S. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.009 · Cited by 27
Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics
Colella, F., Henderson, N. C., & Ramachandran, P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186421 · Cited by 31
“Specific subpopulations of monocyte-derived macrophages upregulate matrix-degrading enzymes such as MMP9, MMP12, and MMP13 and antiinflammatory mediators such as TREM2 to abrogate inflammatory activity and enhance fibrosis regression (118, 169– 172).”
Mechanisms and therapeutic insights into MASH-associated fibrosis
Zhu, Y., & Cai, B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.09.004 · Cited by 32
Kupffer cells in liver homeostasis and disease: from immune sentinels to metabolic gatekeepers
David, B. A., Andreata, F., Blériot, C., Ginhoux, F., Kubes, P., & Iannacone, M. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01288-0 · Cited by 31
Beyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation
Lu, H., Huang, J., Wang, Y.-C., Casals, E., Casals, G., & Zeng, M. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103933 · Cited by 19
“However, some M2 subsets, for example, promote fibrosis through galectin-3-mediated HSC activation [80], and others, like TREM2 + LAMs, exhibit hybrid pro-fibrotic and pro-resolving properties [81].”
TREM2 as a regulator of obesity-induced cardiac remodeling: mechanisms and therapeutic insights
Chung, E., Zhang, D., Porras, M. G., & Hsu, C. G. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00075.2025 · Cited by 18
Yu, X., Tian, W., Bao, X., Li, Z., Tu, H., Xu, X., Chen, J., Zhang, Q., Chen, J., Liu, C., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001427 · Cited by 14
Myeloid cells in chronic liver inflammation
Patseas, D., El-Masry, A., Liu, Z., Ramachandran, P., & Triantafyllou, E. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01324-4 · Cited by 22
“A recent study corroborated the previously established importance [274] of TREM2 in macrophages for fi brosis resolution.”
Salladay-Perez, I. A., Avila, I., Estrada, L., Alexandru, A. C., Ponce, C., Dhingra, A., Torres, G., Deng, C. Y., Hegde, R., Gensheimer, J., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01101-6 · Cited by 32
Zhao, Q., Lu, S., Guan, Y., Sun, Z., Qiu, S., & Zhang, A. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02867-9 · Cited by 17
“Specialized populations such as lipid-associated macrophages, monocyte-derived Kupffer-like cells, and resident Kupffer cells have been identified, moving the field beyond a simple binary view toward a continuum of activation states [24, 25].”
Wang, J., Chen, X.-Y., Zhang, Y., Shen, Y., Zhu, M.-L., Zhang, J., & Zhang, J. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1562848 · Cited by 20
Novel regulators of hepatic macrophages in liver fibrosis
Tang, X., Bai, M., Du, X., Wang, H., Liu, M., Fu, X., Zhang, H., Liang, S., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1705503 · Cited by 12
Guan, Y., Kim, Y. S., Wang, Y., Cho, Y. E., Xiang, X., Kim, S., Yao, T., Feng, D., Hwang, S., & Gao, B. (2025) · Journal of Clinical Investigation · doi:10.1172/jci190635 · Cited by 14
Macrophage heterogeneity and plasticity in liver injury and repair mechanisms
Zhang, T., Horn, P., Peiseler, M., & Tacke, F. (2025) · Stem Cells · doi:10.1093/stmcls/sxaf072 · Cited by 16
Immune activation induced by dysregulated lipid metabolism in the pathogenesis of type 2 diabetes
Yang, H., Yu, W., Mao, Q., & Zhao, L. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.114395 · Cited by 11
GPNMB regulates the differentiation and transformation of monocyte-derived macrophages during MASLD
Wang, J., Wang, H., Yang, W., Zhao, D., Liu, D., Tang, L., & Chen, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114554 · Cited by 12
Myeloid cell path to malignancy: insights into liver cancer
Ramirez, C. F. A., & Akkari, L. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.02.006 · Cited by 12
Reviewing the function of macrophages in liver disease
Chen, L., Guillot, A., & Tacke, F. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2508963 · Cited by 16
“However, based on functional studies in mice, monocyte-derived Trem2+ macrophages in the liver reduce steatohepatitis as well as fibrosis [102] and even promote the resolution of MASH-associated fibrosis after cessation of the metabolic injury [103].”
Zhang, B., Liu, M., Jiang, L., Chen, Z., Tian, W., Li, K., Yu, B., Zhang, W., Li, S., Zhou, Y., et al. (2025) · Current Microbiology · doi:10.1007/s00284-025-04474-w · Cited by 8
Decoding the CHI3L1/IL-13Rα2 signaling nexus in MASH-fibrosis pathogenesis
Zheng, Q., Cao, Y., Jiang, X., Wang, X., Wang, X., He, Y., Ma, W., Wu, H., Jiang, Y., WANG, T., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz3223 · Cited by 14
Lipid-associated macrophages and metabolic inflammatory diseases
Zheng, Y., Tu, D., Dong, C., Zhao, H., & Wang, H. (2026) · Cell Insight · doi:10.1016/j.cellin.2026.100312 · Cited by 14
“LAMs are also important sources of local pro-inflammatory factors such as interleukin-1 β (IL-1 β ), TNF-α , IL-18, CXCL8, and PDGF β that interact with structural and immune cells.”
InfluentialImmunometabolic integration in therapeutic strategies for managing MASLD
González-Serrano, S., Onoiu, A.-I., Camps, J., & Joven, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1693753 · Cited by 8
Boesch, M., Anak, S., Abyad, D. E., Ostyn, T., Antoranz, A., Van, T. M., Newhouse, D., Myers, C., Melkebeke, L. V., Palmer, J. M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02600-3 · Cited by 18
Papachristoforou, E., Kong, K., Colella, F., Tam, J., Luft, J., Sutherland, E. F., Veizades, S. A., Grzelka, M., Qui, P. K., Asif, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.27.671899 · Cited by 7
Zhang, B., Wang, J., Aniwan, A., Zhou, S., Li, Y., Wang, L., Wu, Y., Wang, Z., Zhang, L., Lin, Y., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202501964r · Cited by 7
Lambooij, J. M., Chavanelle, V., Vallier, M., van der Zande, H. J. P., Otero, Y. F., Otto, F., Schuurman, R., Joubioux, F. L., Maugard, T., Giera, M. A., et al. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00033-z · Cited by 7
“LAMs are intimately linked with fi brotic areas in the liver during MASH development and have been shown to play an essential role in the regression of fi brosis 12,57 .”
Zhou, X., Liu, Z., Li, S., Song, Y., Sun, M., Si, Z., & Zhu, W. (2025) · Inflammation Research · doi:10.1007/s00011-025-02155-9 · Cited by 9
“However, TREM2-expressing liver lipid-associated macrophages (LAM) suppress local inflammation and inhibit the progression of liver fibrosis in MASH [ 49].”
The feasibility of targeting macrophage for disease treatment: roles of CEBPD
Fan, T., Lin, S., Zhou, J., Chen, J., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1650161 · Cited by 9
Gong, Y., & Weinberg, S. E. (2025) · Biomolecules · doi:10.3390/biom15121687 · Cited by 10
“These rare populations, which include macrophages [8], hepatic stellate cells (HSCs) [9], tissue-resident memory T cells [10], specialized dendritic cell subsets [11], and localized Treg populations [12], often exert disproportionate functional effects relative to their abundance, yet their…”
Sun, Z., Wang, X., Shi, C., Yu, T., Xu, W., Ji, X., Su, K., Yan, H., Shan, Y., Xie, T., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142306 · Cited by 6
Schonfeld, M., Nataraj, K., Mah, S., Weinman, S., & Tikhanovich, I. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101525 · Cited by 5
Geng, Y., Luo, K., Stam, J., Oosterhuis, D., Gorter, A. R., van den Heuvel, M., Crescitelli, R., de Meijer, V. E., Wolters, J. C., & Olinga, P. (2025) · Journal of Extracellular Biology · doi:10.1002/jex2.70043 · Cited by 5
ETS1 suppresses hepatic stellate cell activation and liver fibrosis
Lee, W., Liu, X., Rosenthal, S. B., Miciano, C., Sakane, S., Hokutan, K., Dhar, D., Kim, H. Y., Brenner, D. A., & Kisseleva, T. (2025) · JCI Insight · doi:10.1172/jci.insight.195242 · Cited by 7
“To evaluate fibrosis resolution, resorption of fibrous scars and myofibroblast inactivation were compared in recovering mice versus CCl 4 -injured mice (14).”
Self-citationTranscriptomic plasticity of cholinergic adipose macrophages in the acute thermogenic response
Knights, A. J., Kim, E. J., Liu, S., & Wu, J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110925 · Cited by 5
Imperfect repair in aging: senescent cells and the hepatic fibrotic niche
Kim, J., Kim, M., & Kim, C. (2026) · BMB Reports · doi:10.5483/bmbrep.2025-0224 · Cited by 6
CD9 regulates macrophage-mediated remodeling of adipose tissue in obesity
Chini, J., DeMarco, N., Mitchell, D. V., McCright, S. J., Shen, K. M., Pandey, D., Clement, R. L., Miller, J., Jain, R., Taylor, D. M., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.193837 · Cited by 8
Li, Y., Nie, L., Lv, T., Zhou, J., Ge, X., Chen, C., Yang, F., Deng, Y., Mao, J., Wang, R., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07096-9 · Cited by 6
“Functionally, TREM2 regulates gene programs involved in phagocytosis, lipid catabolism, and energy metabolism, whereas its deficiency disrupts the downstream activation of the LAM molecular program [27, 28].”
Chen, Y., Zhou, J., Tang, C., Zhu, P., Xu, Z., Song, X., Zhang, J., Cen, L., Zeng, H., Ke, Y., et al. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00824-5 · Cited by 4
“Liver macrophages are considered early responders in the development of steatohepatitis, promoting disease progression through the secretion of proinflammatory mediators [10–12].”
Seo, H.-S., Kim, H.-G., Joo, H.-E., Kwon, J., & Cho, J.-H. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120292 · Cited by 9
Ouyang, R., Li, X., Hao, J., Lin, J., Lan, H. Y., Peng, J., Li, X., Tian, Z., & Sun, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1708240 · Cited by 5
Kupffer cells: Orchestrators of liver physiology
Qin, C., Chen, Y., & Tang, L. (2026) · Liver Research · doi:10.1016/j.livres.2026.01.004 · Cited by 4
Targeting macrophages in liver fibrosis
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835489 · Cited by 3
EASL position paper on preclinical models of steatotic liver disease
Gallage, S., Castro, R. E., Estall, J. L., Tabas, I. A., Anstee, Q. M., TINIAKOS, D. G., Szabó, G., Yu, J., Desdouets, C., Tacke, F., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.029 · Cited by 8
Metabolically and epigenetically reprogrammed splenic TRNP1hiCD8+ T cells exacerbate liver fibrosis
Zhang, L., Wang, Y., Wei, K., Nie, W., Feng, Y., Shi, Z., Xiao, H., Xie, W., Lin, Y. X., Zeng, X., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02660-5 · Cited by 5
Choi, Y., Ma, Y., Tom, S., Danilkovitch, A., & Yu, L. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1579062 · Cited by 2
Impact of metabolic endoscopy on fibrosis regression in steatotic liver disease
Sierra, L., Chatterjee, A., Prado, R., Khurana, A. T., Patel, R., Firkins, S. A., & Simons-Linares, C. R. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i9.108144 · Cited by 3
Dempsey, J. L., Savard, C. E., Kothari, V. M., Tang, J., Lee, S. P., Bornfeldt, K., Carr, R. M., & Ioannou, G. N. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100828 · Cited by 4
TREM2 Deficiency Regulates Macrophage Apoptosis and Repair in Radiation-Induced Skin Injury
Chen, Z., cai, S., Li, P., Zhou, Z., Huang, Z., Deng, J., Jin, L., Luo, Z., Fan, D., Zhou, J., et al. (2025) · Research · doi:10.34133/research.1018 · Cited by 4
Neureiter, D., Kiesslich, T., & Ocker, M. (2026) · Medical Sciences · doi:10.3390/medsci14010110 · Cited by 3
“GPNMB, which also marks LAMs alongside TREM2/CD9/CD14, reflects macrophage-driven fibrogenesis and resolves during fibrosis regression; its plasma levels predict inflammation in lysosomal storage diseases with liver involvement [106].”
Decoding macrophage heterogeneity in the pulmonary fibrosis lung cancer transition
Yu, H., Zhao, M., Li, Q., & Zhang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1787094 · Cited by 7
“As an important pattern recognition receptor, TREM2 recognizes various molecules and associated lipids released during apoptosis or cell damage, thus playing a central role in regulating phagocytosis, metabolism, and in fl ammatory functions of macrophages (61).”
The versatile interplay between steatotic liver disease and liver cancer
Rahbari, M., Gris‐Oliver, A., Ramadori, P., Aicher, D., Sia, D., MALEK, N. P., Loomba, R. S., Bataller, R. A., Llovet, J. M., & Heikenwälder, M. F. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00918-y · Cited by 4
“Nevertheless, this myeloid population likely originates from circulating monocytes and is suggested to replace resident lipid-engulfed dysfunctional Kupffer cells in advanced stages of MASH 118 .”
Self-citationHu, K., Liu, S., Sheng, S., Zhang, S., Li, B., Sun, B., & Xia, A. (2026) · iLiver · doi:10.1016/j.iliver.2026.100234 · Cited by 6
“57,100 Positive modulation of TREM2 through approaches such as agonists or gene enhancement has been proposed as a potential therapeutic strategy, potentially offering a more comprehensive effect than conventional CCR2/CCR5-targeted anti-inflammatory interventions.”
InfluentialThe immunometabolic nature of MASH: framing immune cells within metabolic dysfunction
González-Serrano, S., Onoiu, A.-I., Jiménez-Franco, A., Cambra-Cortés, V., Camps, J., & Joven, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1797949 · Cited by 4
“This activity has been linked to TREM2 + macrophages, which become the dominant subset during the remission phase of MASH in mice (54).”
Wang, D., Jabile, M. J. T., Pastena, F. D., Townsend, L. K., Ahmadi, E., Hoegl, A., Payne, A., Lavoie, D. C. T., Batchuluun, B., Gautam, J., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.07.008 · Cited by 5
Molecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 10
“Notably, subsets of TREM2 + macrophages can also promote fibrosis resolution in rodent models of MASH 213 .”
Therapeutic targeting of myeloid cells in liver fibrosis: Mechanisms and clinical prospects
Wang, Y., Liu, Y., Chen, D., Liu, L., Sun, L., & Zhang, L. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70053 · Cited by 5
“70 In advanced stages, scar-associated macrophages (SAMs), a LAM subset marked by elevated SPP1 (osteopontin) expression, drive fibrosis by activating hepatic stellate cells and depositing ECM components.”
Visiting MASLD through the lens of sex, immunity, and microbial interactions
Puhan, S., Rekha, S. S., Sahu, K., Mohanty, T., De, A. J., Das, A., & Aich, P. (2025) · Discover Medicine · doi:10.1007/s44337-025-00489-1 · Cited by 2
“Disease progression is marked by loss of resident Kupffer cells (KCs) and expansion of monocyte-derived subsets, including moKCs, pre-moKCs, and lipid-associated macrophages (LAMs) [46].”
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Aquino, J. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792423 · Cited by 1
Fu, J., Chen, T., Fang, X., Zhang, S., & Miao, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152682 · Cited by 3
Schonfeld, M. P., Nataraj, K., Mah, S., Zhong, W. H., Weinman, S. A., & Tikhanovich, I. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101689 · Cited by 5
“22,23,25 However, signals required for the emergence of this subset are not clear.”
Zhao, X., Wang, C., Fan, Z., Kong, Q., Feng, L., & Qin, L. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04457-4 · Cited by 3
“Previous research has reported that microenvironmental cues including injury etiology, metabolic conditions, and cytokine profiles, shape the phenotypic and functional traits of Mo-Macs, making them an attractive therapeutic target [7, 42].”
Richard, K. S. E., Rohilla, S., Gade, R., Arias, F., & Rom, O. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01425-z · Cited by 4
“Luckily, the rapid progress currently underway through single-cell transcriptomics [71, 72], alongside emerging techniques like spatially-resolved mass spectrometry imaging [ 78 ], will allow dissection of dysregulated metabolism in specific immune-cell subsets which drive cardiometabolic…”
Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma
Zhang, V. X., Yu, T. C.-Y., Tsui, Y., & Ng, I. O. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.04.010 · Cited by 2
The TREM2 paradox in fibrosis: a unified mechanism for opposite outcomes across organs
Liang, X., Li, Y., Tang, Z., Wang, G., & Liu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1799143 · Cited by 2
“For example, in models of liver fi brosis, TREM2 exhibits anti fi brotic effects by enhancing the collagen-degrading capabilities of macrophages and inhibiting the activation of hepatic stellate cells (14, 15).”
Fallowfield, J. A., Ramachandran, P., & Kendall, T. J. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.05.026 · Cited by 2
Zhang, T., Zhang, M., He, X., & Zhang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1865859 · Cited by 3
Li, X., Jin, K., Fang, J., Ma, X., He, J., Lu, A., Jia, Z., & Shi, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835197 · Cited by 4
Liver Macrophages in the Pathogenesis of Viral Hepatitis
Tsomidis, I., Tsakou, A., Voumvouraki, A., & Kouroumalis, E. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48070687 · Cited by 2
“LAMs were initially identified in adipose tissue [58].”
Shi, L., Zhou, H., & Zheng, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1793796 · Cited by 2
Gaston, L. S., Jorgensen, B., Friedman, H., Sherman, M. S., & Majzoub, J. A. (2026) · Endocrinology · doi:10.1210/endocr/bqag081
Gerardin, Y., Stanford-Moore, A., Patel, N., Zhang, Y., Zhang, J., Mistry, P. N., Kartik, D., Liu, Y., Indorf, N., Fahy, D., et al. (2025) · medRxiv · doi:10.1101/2025.06.12.25328580 · Cited by 1
“…work has suggested that changes in liver composition not captured by standard scoring guidelines (lipid-associated macrophages and antigen-dependent CD8+ lymphocytes [5,6]) are relevant to metabolic dysfunction-associated steatohepatitis (MASH), these changes cannot be quantified by the human eye.”
Hamon, P., Park, M. D., Bérichel, J. L., Cohen, M., Soong, B. Y., Buckup, M., Hennequin, C., Lindblad, K. E., Mattiuz, R., Figueiredo, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.09.675071 · Cited by 2
Modeling Fibrosis with MASH Patient Liver-Derived OrganoidsPreprint
Liu, A., Haseman, A. D. T., Bantu, K., Nong, J., Muzykantov, V. R., Melamed, J. R., Kegel, M., Muscat-Rivera, J., Weissman, D., Smith, D. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.18.677209 · Cited by 1
“However, unlike in humans, TREM2 + CD68 + MPs in mice have recently been implicated in fibrosis resolution and thus assigned an anti-inflammatory function (13).”
Dib, L. H., Zurke, Y.-X., & Monaco, C. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag289 · Cited by 1
Zhang, L., Liu, S., Zhao, Q., Liu, X.-Y., Liu, T., Zhang, Q., Liu, M.-H., & Zhao, W. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i2.102328
Lambooij, J. M., Chavanelle, V., Vallier, M., van der Zande, H. J. P., Otero, Y. F., Otto, F., Schuurman, R., Joubioux, F. L., Maugard, T., Giera, M. A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6285712/v1
Zhong, X., Lu, J., Yang, X., Chen, H., Wang, W., Jun, Z., Zhao, Q., & Zhu, L. (2026) · Hepatology International · doi:10.1007/s12072-025-11024-w · Cited by 1
“J), which were markers with restorative macrophages that play a role in coordinating fibrosis regression, but regress during fibrosis progression [16].”
A Druggable G Protein Checkpoint in Cholesterol EffluxPreprint
Katkar, G. D., Anandachar, M. S., Espinoza, C. R., Estanol, M. L., Biggs, C., Nacayama, M., Hsu, S.-T., Tam, E., Mukharjee, R., McLaren, E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.15.705962
Myeloid KIF13B suppresses the STT3A/CTSD/THBS1 axis to prevent MASH
Lu, K., Shen, X., Guo, Z., Chen, J., He, L., Xian, A., Mei, S., Han, Y., Zhao, Y., Chen, J., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001726 · Cited by 3
Ganguly, S., Gunes, B. B., Gu, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.26.708088
“Previous research has demonstrated that dietary intervention significantly ameliorates MetS, MASH, liver fibrosis, and related signaling pathways in the liver 15,16 .”
Self-citationTong, Y., Mu, F., Wang, C., Sang, T., Sun, X., Feng, Z., Cai, G., Chen, X., & Ouyang, Q. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.17.712275 · Cited by 1
“Furthermore, some studies reported that Trem2 deficiency exacerbates steatohepatitis and liver fibrosis by increasing TGF-β 1 secretion 40 and impaired collagenolytic activities against CollagenIV 38,41 .”
Yang, M., Olaoba, O. T., Chinwo, S., LeVasseur, H. L., Zhou, B., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i14.117396
Palmitoleic acid promoted by BMPR2 signaling primes CD169 macrophages and alleviates liver fibrosis
Ma, H., Zhong, J., Peng, Q., Dai, M., Wang, L., Wang, J., Huang, D., Liu, Y., Tang, Y., Xu, W., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09972-6 · Cited by 1
Metadata
- Authors
- Ganguly, S., Rosenthal, S. B., Ishizuka, K., Troutman, T. D., Rohm, T. V., Khader, N., Aleman-Muench, G., Sano, Y., Archilei, S., Soroosh, P., Olefsky, J. M., Feldstein, A. E., Kisseleva, T., Loomba, R., Glass, C. K., Brenner, D. A., & Dhar, D.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of California San Diego (US)
- Cincinnati Children's Hospital Medical Center (US)
- Cardiovascular and Metabolism discovery, Immunometabolism, Janssen Research & Development, La Jolla, CA 92121
- Corresponding author
- Glass, Christopher K.
- Brenner, David A.
- Dhar, Debanjan
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2024-08-22
- Volume
- 121
- Issue
- 35
- Pages
- e2405746121-e2405746121
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC11363294
- OpenAlex
- W4401753386
- Cited by
- 145
- References
- 44
- Citations by year
- 2026: 80 · 2025: 62 · 2024: 3
- FWCI
- 37.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK137061 R01DK133930DK091183)
- HHS | NIH | National Heart, Lung, and Blood Institute (HL147835)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- TREM2, nonalcoholic steatohepatitis, lipid-associated macrophages, Kupffer cells, monocyte-derived macrophages, macrophage heterogeneity, crown-like structures, collagen degradation, hepatic steatosis, phagocytosis, lipid handling, liver inflammation
- MeSH terms
- Animals, Fatty Liver, Kupffer Cells, Lipids, Liver, Liver Cirrhosis, Macrophages, Male, Membrane Glycoproteins, Mice, Inbred C57BL, Receptors, Immunologic, Mice, Knockout, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.